Replies to post #141 on Amylyx Pharmaceuticals Inc (AMLX)

[Whalatane]

Well stock may be trailing off due to this recent statement by Ceo

Our previous estimates assumed a ramp in the enrollment rate at this stage of the trial, but we have seen more of a steady enrollment rate in the last few weeks.

So maybe longer to trial completion and data then what they previously projected
Kiwi

[Whalatane]

Karen Firestone just made an Open Market purchase

Karen Firestone is a regular contributor on CNBC and appears frequently on the network's programs. She is also a Director on the board of Amylyx Pharmaceuticals (AMLX).
CNBC Contributor: Ms. Firestone appears on shows such as the Half Time Report, Squawk Box, and Worldwide Exchange. She also writes for the CNBC.com website.
Amylyx Director: She has served as an independent director on the Amylyx Pharmaceuticals board since March 2023.
In addition to these roles, she is the Co-founder and Chair Emerita of Aureus Asset Management.

Kiwi